APPLICATION
ANDA211574
TYPE
ANDA
ORIGINAL APPROVAL
2021-02-11
LATEST ACTION
2021-02-11
ROUTE
INTRAVENOUS, SUBCUTANEOUS, INTRAVENOUS, SUBCUTANEOUS
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
TREPROSTINILPrescription
TREPROSTINIL 5MG/ML · INJECTABLE · INTRAVENOUS, SUBCUTANEOUS
TREPROSTINILPrescription
TREPROSTINIL 1MG/ML · INJECTABLE · INTRAVENOUS, SUBCUTANEOUS
TREPROSTINILPrescription
TREPROSTINIL 10MG/ML · INJECTABLE · INTRAVENOUS, SUBCUTANEOUS
TREPROSTINILPrescription
TREPROSTINIL 2.5MG/ML · INJECTABLE · INTRAVENOUS, SUBCUTANEOUS
Approval history
2021-02-11UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.